Histopathologic and immunologic effects of the itraconazole treatment in a murine model of chronic pulmonary paracoccidioidomycosis

Microbes and Infection

Volumn 12, Issue 14-15, 2010, Pages 1153-1162

  Naranjo, Tonny W ^a,b   Lopera, Damaris E ^a   Diaz Granados, Lucy R ^b   Duque, Jhon J ^c   Restrepo, Angela ^a   Cano, Luz E ^a,c  

^a Unidad de Biología Celular y Molecular   (Colombia)

^b UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Cytokines; Itraconazole; Lung fibrosis; Paracoccidioidomycosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 1BETA; ITRACONAZOLE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNE RESPONSE; LUNG FIBROSIS; LUNG INFECTION; MOUSE; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PRIORITY JOURNAL; SOUTH AMERICAN BLASTOMYCOSIS;

ANIMALS; ANTIFUNGAL AGENTS; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCYTOCHEMISTRY; ITRACONAZOLE; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C; MICROSCOPY; PARACOCCIDIOIDES; PARACOCCIDIOIDOMYCOSIS;

ANIMALIA; MURINAE; MUS; PARACOCCIDIOIDES BRASILIENSIS;

EID: 78649898793     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.07.013     Document Type: Article

References (50)

1. Richardson M.D. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother. 2005, 56:5-11.
2. Brummer E., Castañeda E., Restrepo A. Paracoccidioidomycosis: an update. Clin. Microbiol. Rev. 1993, 6:89-117.
3. Caramori S.M., Teixeira R., Afonso J., Carraro R., Strabelli T., Samano M., Pêgo-Fernandes P., Jatene F. Bacterial and fungal pneumonias after lung transplantation. Transplant. Proc. 2008, 40:822-824.
4. Matute D.R., Quesada-Ocampo L.M., Rauscher J.T., McEwen J.G. Evidence for positive selection in putative virulence factors within the Paracoccidioides brasiliensis species complex. PLoS Negl. Trop. Dis. 2008, 17:296.
5. Borges-Walmsley M.I., Chen D., Shu X., Walmsley A.R. The pathobiology of Paracoccidioides brasiliensis. Trends Microbiol. 2002, 10:80-87.
6. Franco M.M., Montenegro R., Mendes R.P., Marques S.A., Dillon N.L., Mota N.G. Paracoccidioidomycosis: a recently proposed classification of its clinical forms. Rev. Soc. Bras. Med. Trop. 1987, 20:129-132.
7. Restrepo S., Tobón A., Trujillo J., Restrepo A. Development of pulmonary fibrosis in mice during infection with Paracoccidioides brasiliensis conidia. J. Med. Vet. Mycol. 1992, 30:173-184.
8. Parise-Fortes M.R., Marques S.A., Soares A.M., Kurukawa C.S., Marques M.E., Peracoli M.T. Cytokines released from blood monocytes and expressed in mucocutaneous lesions of patients with paracoccidioidomycosis evaluated before and during trimethoprim-sulfamethoxazole treatment. Br. J. Dermatol. 2006, 154:643-650.
9. Oliveira S.J., Mamoni R.L., Musatti C.C., Papaiordanou P.M., Blotta M.H. Cytokines and lymphocyte proliferation in juvenile and adult forms of paracoccidioidomycosis. Comparison with infected and non-infected controls. Microbes Infect. 2002, 4:139-144.
10. Calvi S.A., Soares A.M., Peraçoli M.T., Mendes R.P. Effect of cytokines on the in vitro fungicidal activity of monocytes from paracoccidioidomycosis patients. Microbes Infect. 2003, 5:107-113.
11. Mello L.M., Vergara M.L.S., Rodrigues J.V. Patients with active infection with Paracoccidioides brasiliensis immune response characterized by high interleukin 4 and interleukin 5 production. Hum. Immunol. 2002, 63:149-154.
12. Karhawi S.A., Colombo A.L., Salomano R. Production of IFN-gamma is impaired in patients with paracoccidioidomycosis during active disease and is restored after clinical remission. Med. Mycol. 2002, 38:225-229.
13. Benard G., Romano C.C., Cacere C.R., et al. Imbalance of IL-2, IFN-gamma and IL-10 secretion in the immunosuppression associated with human paracoccidioidomycosis. Cytokine 2001, 13:248-252.
14. Peraçoli M.T., Kurokawa C.S., Calvi S.A., et al. Production of pro and anti-inflammatory cytokines by monocytes from patients with paracoccidioidomycosis. Microbes Infect. 2003, 5:8-13.
15. Fornazim M.C., Balthazar A., Quagliato J.R., et al. Evaluation of bronchoalveolar cells in pulmonary paracoccidioidomycosis. Eur. Respir. J. 2003, 822:895-899.
16. McEwen J.G., Bedoya V., Patiño M.M., Salazar M.E., Restrepo A. Experimental murine paracoccidioidomycosis induced by the inhalation of conidia. J. Med. Vet. Mycol. 1987, 25:165-175.
17. Franco L., Najvar L., Gómez B., Restrepo S., Graybill J.R., Restrepo A. Experimental pulmonary fibrosis induced by Paracoccidioides brasiliensis conidia: measurement of the host local responses. Am. J. Trop. Med. Hyg. 1998, 58:424-430.
18. Cock A.M., Cano L.E., Vélez D., Aristizábal B., Trujillo J., Restrepo A. Fibrotic sequelae in pulmonary paracoccidioidomycosis: histopathological aspects in BALB/c mice infected with viable and non-viable propagules. Rev. Inst. Med. Trop. Sao Paulo 2000, 42:59-66.
19. González A., Restrepo A., Cano L.E. Pulmonary immune responses induced in BALB/c mice by Paracoccidioides brasiliensis conidia. Mycopathologia 2008, 165:313-330.
20. Menezes V.M., Soares B., Fontes C. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst. Rev. Apr 19 2006, CD004967.
21. Queiroz-Telles F., Goldani L.Z., Schlamm H.T., Goodrich J.M., Espinel-Ingroff A., Shikanai-Yasuda M.A. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin. Infect. Dis. 2007, 45:1462-1469.
22. De Beule K., Van Gestel J. Pharmacology of itraconazole. Drugs 2001, 61:27-37.
23. Khan Z.K., Jain P. Antifungal agents and immunomodulators in systemic mycoses. Indian J. Chest Dis. Allied Sci. 2000, 242:345-355.
24. Tobón A.M., Agudelo C.A., Osorio M.L., Alvarez D.L., Arango M., Cano L.E., Restrepo A. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. Clin. Infect. Dis. 2003, 37:898-904.
25. McEwen J.G., Peters G.R., Blaschke T.F., Brummer E., Perlman A.M., Restrepo A., Stevens D.A. Treatment of paracoccidioidomycosis with itraconazole in a murine model. J. Trop. Med. Hyg. 1985, 88:295-299.
26. Restrepo S., Tabares A.M., Restrepo A. Activity of two different triazoles in a murine model of paracoccidioidomycosis. Rev. Inst. Med. Trop. Sao Paulo 1992, 34:171-176.
27. Martinez R., Malta M.H., Verceze A.V., Arantes M.R. Comparative efficacy of fluconazole and amphotericin B in the parenteral treatment of experimental paracoccidioidomycosis in the rat. Mycopathologia 1999, 146:131-134.
28. Scavone R., Burger E. Paracoccidioidomycosis: reduction in fungal load and abrogation of delayed-type hypersensitivity anergy in susceptible inbred mice submitted to therapy with trimethoprim-sulfamethoxazole. Med. Microbiol. Immunol. 2004, 193:53-59.
29. Restrepo A., Salazar M.E., Cano L.E., Patiño M.M. A technique to collect and dislodge conidia produced by Paracoccidioides brasiliensis mycelial form. J. Med. Vet. Mycol. 1986, 24:247-250.
30. Heykants J., Van Peer A., Van de Velde V., et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989, 32:67-87.
31. Alves L.M., Figueiredo F., Brandão Filho S.L., Tincani I., Silva C.L. The role of fractions from Paracoccidioides brasiliensis in the genesis of inflammatory response. Mycopathologia 1987, 97:3-7.
32. Silva C.L., Alves L.M., Figueiredo F. Involvement of cell wall glucans in the genesis and persistence of the inflammatory reaction caused by the fungus Paracoccidioides brasiliensis. Microbiology 1994, 140:1189-1194.
33. Moscardi-Bacchi M., Soares A., Mendes R., Marques S., Franco M. In situ localization of T lymphocyte subsets in paracoccidioidomycosis. J. Med. Vet. Mycol. 1989, 27:149-158.
34. González A., De Gregori W., Vélez D., Restrepo A., Cano L.E. Nitric oxide participation in the fungicidal mechanism of gamma interferon-activated murine macrophages against Paracoccidioides brasiliensis conidia. Infect. Immun. 2000, 68:2546-2552.
35. González A., Aristizábal B.H., Caro E., Restrepo A., Cano L.E. TNF-α-activated macrophages inhibit transition of Paracoccidioides brasiliensis conidia to yeast cells through a mechanism independent of nitric oxide. J. Trop. Med. Hyg. 2004, 71:828-830.
36. Moscardi-Bacchi M., Brummer E., Stevens D.A. Support of Paracoccidioides brasiliensis multiplication by human monocytes or macrophages: inhibition by activated phagocytes. J. Med. Microbiol. 1994, 40:159-164.
37. Saunders B.M., Frank A.A., Orme I.M. Granuloma formation is required to contain bacillus growth and delay mortality in mice chronically infected with Mycobacterium tuberculosis. Immunology 1999, 98:324-328.
38. Calich V.L., Kashino S.S. Cytokines produced by susceptible and resistant mice in the course of Paracoccidioides brasiliensis infection. Braz. J. Med. Biol. Res. 1998, 31:615-623.
39. Kurita N., Oarada M., Miyaji M., Ito E. Effect of cytokines on antifungal activity of human polymorphonuclear leukocytes against yeast cells of Paracoccidioides brasiliensis. Med. Mycol. 2000, 38:177-182.
40. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 1999, 162:3504-3511.
41. Phillips K., Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Care Res. 2005, 53:618-620.
42. Lucchiari M.A., Modolell M., Eichmann K., Pereira C.A. In vivo depletion of interferon-gamma leads to susceptibility of A/J mice to mouse hepatitis virus 3 infection. Immunobiology 1992, 185:475-482.
43. Mody C.H., Tyler C.L., Sitrin R.G., Jackson C., Toews G.B. Interferon-γ activates rat alveolar macrophages for anti-cryptococcal activity. Am. J. Respir. Cell Mol. Biol. 1991, 5:19-26.
44. Cano L.E., Kashino S.S., Arruda C., André D., Xidieh C.F., Singer-Vermes L.M., Vaz C.A., Burger E., Calich V.L. Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis. Infect. Immun. 1998, 66:800-806.
45. Kaviratne M., Hesse M., Leusink M., Cheever A.W., Davies S.J., McKerrow J.H., Wakefield L.M., Letterio J.J., Wynn T.A. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J. Immunol. 2004, 173:4020-4029.
46. Malavia N.K., Mih J.D., Raub C.B., Dinh B.T., George S.C. IL-13 induces a bronchial epithelial phenotype that is profibrotic. Respir. Res. 2008, 9:27.
47. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
48. Koli K., Myllärniemi M., Keski-Oja J., Kinnula V.L. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal. 2008, 10:333-342.
49. Decologne N., Kolb M., Margetts P.J., Menetrier F., Artur Y., Garrido C., Gauldie J., Camus P., Bonniaud P. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J. Immunol. 2007, 179:6043-6051.
50. Tobón A.M., Gómez I., Franco L., Restrepo A. Seguimiento post-terapia en pacientes com Paracoccidioidomicosis tratados con itraconazol. Rev. Colomb. Pneumol. 1985, 7:74-78.